Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Drop in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 419,600 shares, a drop of 42.9% from the November 30th total of 735,400 shares. Based on an average trading volume of 702,800 shares, the days-to-cover ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners dropped their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Vincerx Pharma Stock Performance

Shares of NASDAQ VINC traded up $0.01 during midday trading on Friday, reaching $0.19. 17,339,961 shares of the stock were exchanged, compared to its average volume of 746,792. Vincerx Pharma has a twelve month low of $0.18 and a twelve month high of $9.37. The stock has a market capitalization of $6.53 million, a P/E ratio of -0.19 and a beta of 1.48. The company has a 50 day simple moving average of $0.28 and a 200 day simple moving average of $0.52.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 328,533 shares of the company’s stock after buying an additional 256,967 shares during the period. Marshall Wace LLP owned approximately 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent quarter. 44.02% of the stock is owned by hedge funds and other institutional investors.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.